You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港A兩地中藥股大漲,同仁堂、精華製藥等多股漲停
格隆匯12月31日丨港A兩地中藥股大漲,精華製藥、新天藥業、同仁堂、華潤三九、太極集團等多股漲停。港股方面,同仁堂科技漲14%、固生堂漲13.4%、中國中藥漲12%、同仁堂國藥漲9.6%。消息面上,上海等7省(市)成首批獲准建設國家中醫藥綜合改革示範區。近日,國內幾大知名藥企的中成藥價格上調,上漲幅度為10%到20%,其中不乏一些常見品種。券商分析認為,在政策支持、提價催化下,估值較低、品牌影響力強的中醫藥企業受到重視。近兩年,多項鼓勵政策發佈,中醫藥行業迎來發展新機遇,企業經營有望改善。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.